X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (526) 526
Publication (23) 23
Newsletter (5) 5
Newspaper Article (5) 5
Book / eBook (4) 4
Government Document (4) 4
Book Review (3) 3
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (298) 298
index medicus (225) 225
male (221) 221
female (213) 213
chlorobenzenes - adverse effects (181) 181
chlorobenzenes - administration & dosage (162) 162
adult (138) 138
middle aged (127) 127
chlorobenzenes - therapeutic use (125) 125
animals (120) 120
chlorobenzene (117) 117
environmental sciences (112) 112
benzyl alcohols - administration & dosage (99) 99
pulmonary disease, chronic obstructive - drug therapy (87) 87
administration, inhalation (86) 86
aged (83) 83
drug combinations (80) 80
toxicology (76) 76
respiratory system (71) 71
chlorobenzenes (69) 69
chlorobenzenes - toxicity (67) 67
time factors (67) 67
treatment outcome (67) 67
benzyl alcohols - adverse effects (65) 65
androstadienes - administration & dosage (64) 64
analysis (63) 63
double-blind method (62) 62
vilanterol (61) 61
pharmacology & pharmacy (56) 56
benzyl alcohols - therapeutic use (52) 52
pulmonary disease, chronic obstructive - physiopathology (52) 52
copd (51) 51
benzodiazepinones - therapeutic use (50) 50
adolescent (48) 48
benzodiazepinones - adverse effects (48) 48
bronchodilator agents - administration & dosage (47) 47
drug therapy, combination (45) 45
rats (45) 45
chronic obstructive pulmonary disease (44) 44
dose-response relationship, drug (44) 44
lung diseases, obstructive (44) 44
asthma (42) 42
drug therapy (41) 41
adrenergic beta-2 receptor agonists - administration & dosage (40) 40
androstadienes - adverse effects (39) 39
clinical trials as topic (39) 39
safety (39) 39
benzodiazepinones - administration & dosage (38) 38
quinuclidines - administration & dosage (38) 38
administration, oral (37) 37
chlorobenzenes - analysis (36) 36
obstructive pulmonary-disease (36) 36
bronchodilator agents - adverse effects (34) 34
chlorobenzenes - pharmacology (34) 34
adrenergic beta-2 receptor agonists - adverse effects (33) 33
asthma - drug therapy (33) 33
fluticasone furoate (33) 33
child (32) 32
research (32) 32
toxicity (32) 32
bronchodilator agents - therapeutic use (31) 31
efficacy (31) 31
chlorobenzenes - pharmacokinetics (30) 30
drug administration schedule (30) 30
forced expiratory volume - drug effects (30) 30
engineering, environmental (29) 29
glucocorticoids - administration & dosage (29) 29
tiotropium (29) 29
corticosteroids (28) 28
forced expiratory volume (28) 28
chlorobenzenes - chemistry (27) 27
chlorobenzenes - metabolism (27) 27
fatigue - chemically induced (27) 27
pulmonary/respiratory (27) 27
quinuclidines - adverse effects (27) 27
androstadienes - therapeutic use (26) 26
nitro compounds - therapeutic use (26) 26
risk assessment (26) 26
young adult (26) 26
benzene (25) 25
chlorbenzol (25) 25
studies (25) 25
tranquilizing agents - adverse effects (25) 25
glucocorticoids - adverse effects (24) 24
kinetics (24) 24
lung-function (24) 24
anticonvulsants - adverse effects (23) 23
anticonvulsants - therapeutic use (23) 23
care and treatment (23) 23
degradation (23) 23
environment (23) 23
quinuclidines - therapeutic use (23) 23
tranquilizing agents - therapeutic use (23) 23
umeclidinium (23) 23
adrenergic beta-2 receptor agonists - therapeutic use (22) 22
double-blind (22) 22
epilepsy - drug therapy (22) 22
mice (22) 22
muscarinic antagonists - administration & dosage (22) 22
nitro compounds - administration & dosage (22) 22
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (507) 507
German (14) 14
Russian (11) 11
French (5) 5
Polish (3) 3
Portuguese (2) 2
Spanish (2) 2
Chinese (1) 1
Czech (1) 1
Danish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 18, pp. 1671 - 1680
The frequency of COPD exacerbations during treatment with a triple inhaler — delivering a long-acting beta-agonist (LABA), a long-acting muscarinic antagonist... 
MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | PARALLEL-GROUP | DOUBLE-BLIND | TIOTROPIUM | RANDOMIZED CONTROLLED-TRIAL | FLUTICASONE PROPIONATE/SALMETEROL | SALMETEROL | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - administration & dosage | Hospitalization - statistics & numerical data | Male | Dyspnea - etiology | Quinuclidines - administration & dosage | Chlorobenzenes - administration & dosage | Adrenergic beta-Agonists - administration & dosage | Adult | Female | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Glucocorticoids - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Pulmonary Disease, Chronic Obstructive - complications | Muscarinic Antagonists - administration & dosage | Androstadienes - administration & dosage | Intention to Treat Analysis | Quality of Life | Dyspnea - drug therapy | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Treatment outcome | Lung diseases, Obstructive | Care and treatment | Usage | Analysis | Diagnosis | Inhalers | Pneumonia | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Critical care | Fluticasone | Patients | Quality of life | Medicine | Hospitals | Obstructive lung disease | Population | Chronic obstructive pulmonary disease | Drug dosages | Life Sciences | Human health and pathology | Pulmonology and respiratory tract
Journal Article
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 210 - 223
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 10, pp. 1538 - 1546
Summary Study objective To examine the efficacy and safety of the once-daily, inhaled, long-acting muscarinic antagonist/β2 -agonist combination... 
Pulmonary/Respiratory | Muscarinic antagonist | Long-acting bronchodilator | β-agonist | Randomised | Fixed-dose combination | COPD | INDACATEROL | LUNG | CARDIAC & CARDIOVASCULAR SYSTEMS | DYSPNEA | BRONCHODILATION | SPIROMETRY | COMBINATION | REFERENCE VALUES | SAMPLE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TIOTROPIUM | beta-agonist | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Benzyl Alcohols - therapeutic use | Quinuclidines - administration & dosage | Chlorobenzenes - administration & dosage | Vital Capacity - drug effects | Quinuclidines - therapeutic use | Female | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Quinuclidines - adverse effects | Severity of Illness Index | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Chlorobenzenes - adverse effects | Chlorobenzenes - therapeutic use | Quality of Life | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Confidence intervals | Smooth muscle | Chronic obstructive pulmonary disease | Drug therapy | Drug dosages
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2015, Volume 109, Issue 9, pp. 1155 - 1163
Abstract Objective The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efficacy and safety of umeclidinium (UMEC 62.5 μg and 125 μg) added... 
Pulmonary/Respiratory | Bronchodilation | Long-acting muscarinic antagonist | Long-acting beta2 agonist | Inhaled corticosteroid | Long-acting beta | agonist | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | MU-G | COMBINATION THERAPY | Long-acting beta agonist | LUNG-FUNCTION | COPD ASSESSMENT TEST | LONG-ACTING BRONCHODILATORS | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | PROPIONATE/SALMETEROL | OUTCOMES | Glucocorticoids - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Benzyl Alcohols - therapeutic use | Quinuclidines - administration & dosage | Dose-Response Relationship, Drug | Vital Capacity - drug effects | Quinuclidines - therapeutic use | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Drug Therapy, Combination | Glucocorticoids - adverse effects | Quinuclidines - adverse effects | Double-Blind Method | Muscarinic Antagonists - administration & dosage | Chlorobenzenes - adverse effects | Chlorobenzenes - therapeutic use | Quality of Life | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Clinical trials | Consulting services | Lung diseases | Steroids | Studies | Chronic obstructive pulmonary disease | Drug dosages | Respiratory diseases | Mortality
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 12, pp. 1752 - 1760
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 4, pp. 560 - 569
Summary Background Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled corticosteroid/long-acting β2 -agonist combination therapy for COPD.... 
Pulmonary/Respiratory | ICS | Once-daily | Lung function | Dose-range | LABA | COPD | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | EFFICACY | SAFETY | SALMETEROL | PROPIONATE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | Bronchodilator Agents - therapeutic use | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Benzyl Alcohols - therapeutic use | Dose-Response Relationship, Drug | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Double-Blind Method | Treatment Outcome | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Chlorobenzenes - therapeutic use | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Clinical trials | Respiratory agents | Lung diseases, Obstructive | Corticosteroids | Chronic obstructive pulmonary disease | Infections | Antibiotics | Oxygen therapy | Drug therapy | Mortality
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 4, pp. 550 - 559
Summary Background Once-daily combination treatment is an attractive maintenance therapy for COPD. However, the dose of inhaled corticosteroid to use in a... 
Pulmonary/Respiratory | ICS | Once-daily | Lung function | Dose-range | LABA | COPD | CORD | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | INHALED CORTICOSTEROIDS | PNEUMONIA | FUROATE | SALMETEROL | PROPIONATE | OBSTRUCTIVE PULMONARY-DISEASE | THERAPY | RESPIRATORY SYSTEM | TIOTROPIUM | ASTHMA | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Benzyl Alcohols - therapeutic use | Chlorobenzenes - administration & dosage | Dose-Response Relationship, Drug | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Drug Therapy, Combination | Glucocorticoids - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Treatment Outcome | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Chlorobenzenes - therapeutic use | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Corticosteroids | Studies | Chronic obstructive pulmonary disease | Infections | Oxygen therapy | Drug therapy | Asthma
Journal Article
Thorax, ISSN 0040-6376, 04/2014, Volume 69, Issue 4, pp. 312 - 319
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 8, pp. 1171 - 1179
Summary Background Fluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting beta2 -agonist (ICS/LABA), recently approved as once-daily... 
Pulmonary/Respiratory | Head-to-head | Long-acting β2-agonist | Chronic obstructive pulmonary disease | Lung function | Inhaled corticosteroid | VILANTEROL | CARDIAC & CARDIOVASCULAR SYSTEMS | MU-G | LUNG-FUNCTION | RANDOMIZED-TRIAL | PERSISTENT ASTHMA | Long-acting beta-agonist | FUROATE | SALMETEROL | RESPIRATORY SYSTEM | EXACERBATIONS | AGONIST | Glucocorticoids - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Chlorobenzenes - administration & dosage | Vital Capacity - drug effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Albuterol - administration & dosage | Female | Glucocorticoids - adverse effects | Dry Powder Inhalers | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Albuterol - analogs & derivatives | Treatment Outcome | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Fluticasone-Salmeterol Drug Combination | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Corticosteroids | Studies | Confidence intervals | Drug therapy
Journal Article
Journal Article